Rufa Magdalena I, Ursulescu Adrian, Dippon Juergen, Aktuerk Dincer, Nagib Ragi, Albert Marc, Franke Ulrich F W
Department of Cardiovascular Surgery, Robert Bosch Hospital, Stuttgart, Germany.
Institute for Stochastic and Applications, Stuttgart University, Stuttgart, Germany.
Front Cardiovasc Med. 2024 Aug 29;11:1385108. doi: 10.3389/fcvm.2024.1385108. eCollection 2024.
The safety and efficacy of minimally invasive direct coronary artery bypass (MIDCAB) surgery has been confirmed in numerous reports. However, minimally invasive multi-vessel off-pump coronary artery bypass grafting (MICS CABG) has lower uptake and has not yet gained widespread adoption. The study aimed to investigate the non-inferiority of MICS CABG to MIDCAB in long-term follow-up for several clinical outcomes, including angina pectoris, major adverse cardiac and cerebrovascular events (MACCE) and overall survival.
This is an observational, retrospective, single center study of 1,149 patients who underwent either MIDCAB ( = 626) or MICS CABG ( = 523) at our institution between 2007 and 2018. The left internal thoracic artery and portions of the radial artery and saphenous vein were used for the patients' single-, double-, or triple-vessel revascularization procedures. We used gradient boosted propensity-score estimation to account for possible interactions between variables. After propensity-score adjustment, the two groups were similar in terms of preoperative demographics and risk profile. Long-term follow-up (mean 5.87, median 5.6 years) was available for 1,089 patients (94.8%).
A total of 626, 454 and 69 patients underwent single, double and triple coronary revascularization, respectively. The long-term outcomes of freedom from angina pectoris, acute myocardial infarction, and revascularization rate were similar between the two groups. During follow-up, there were 123 deaths in the MIDCAB group and 96 in the MICS CABG group. The 1-, 3-, 5-, and 10-year survival rates were 97%, 92%, 85%, and 69% for the MIDCAB group and 97%, 93%, 89%, and 74% for the MICS CABG group, respectively. The hazard ratio of overall survival for patients with two or more bypass grafts compared to those with one bypass graft was 1.190 (-value = 0.234, 95% CI: 0.893-1.586). This indicates that there was no significant difference in survival between the two groups. Furthermore, if we consider a hazard ratio of 1.2 to be clinically non-relevant, surgery with two or more grafts was significantly non-inferior to surgery with just one graft (-value = 0.0057).
In experienced hands, MICS CABG is a safe and effective procedure. Survival and durability are comparable with MIDCAB.
微创直接冠状动脉旁路移植术(MIDCAB)的安全性和有效性已在众多报告中得到证实。然而,微创非体外循环多支冠状动脉旁路移植术(MICS CABG)的应用率较低,尚未得到广泛采用。本研究旨在探讨MICS CABG与MIDCAB在包括心绞痛、主要不良心脑血管事件(MACCE)和总生存率等多项临床结局的长期随访中的非劣效性。
这是一项观察性、回顾性、单中心研究,纳入了2007年至2018年间在本机构接受MIDCAB(n = 626)或MICS CABG(n = 523)的1149例患者。左内乳动脉以及部分桡动脉和大隐静脉用于患者的单支、双支或三支血管血运重建手术。我们使用梯度增强倾向评分估计来考虑变量之间可能的相互作用。经过倾向评分调整后,两组在术前人口统计学和风险特征方面相似。1089例患者(94.8%)获得了长期随访(平均5.87年,中位数5.6年)。
分别有626例患者、454例患者和69例患者接受了单支、双支和三支冠状动脉血运重建。两组在无心绞痛、急性心肌梗死和血运重建率方面的长期结局相似。随访期间,MIDCAB组有123例死亡,MICS CABG组有96例死亡。MIDCAB组的1年生存率、3年生存率、5年生存率和10年生存率分别为97%、92%、85%和69%,MICS CABG组分别为97%、93%、89%和74%。与接受单支旁路移植的患者相比,接受两支或更多支旁路移植的患者的总生存风险比为1.19(P值 = 0.234,95% CI:0.893 - 1.586)。这表明两组在生存率方面无显著差异。此外,如果我们将风险比1.2视为临床不相关,那么接受两支或更多支移植的手术明显不劣于仅接受一支移植的手术(P值 = 0.0057)。
在经验丰富的医生手中,MICS CABG是一种安全有效的手术。生存率和耐久性与MIDCAB相当。